{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T07:05:33Z","timestamp":1782803133269,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,6,28]],"date-time":"2020-06-28T00:00:00Z","timestamp":1593302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,28]],"date-time":"2020-06-28T00:00:00Z","timestamp":1593302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s00345-020-03314-9","type":"journal-article","created":{"date-parts":[[2020,6,28]],"date-time":"2020-06-28T13:02:38Z","timestamp":1593349358000},"page":"1233-1239","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["An evaluation of the federal adverse events reporting system data on adverse effects of 5-alpha reductase inhibitors"],"prefix":"10.1007","volume":"39","author":[{"given":"Matthew B.","family":"Harrell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaylee","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis E.","family":"Te","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0515-2578","authenticated-orcid":false,"given":"Bilal","family":"Chughtai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,28]]},"reference":[{"key":"3314_CR1","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.jsxm.2016.07.006","volume":"13","author":"L Liu","year":"2016","unstructured":"Liu L, Zhao S, Li F et al (2016) Effect of 5\u03b1-reductase inhibitors on sexual function: a meta-analysis and systematic review of randomized controlled trials. J Sex Med 13:1297\u20131310","journal-title":"J Sex Med"},{"key":"3314_CR2","unstructured":"Total Patient Tracker (TPT) Years 2002-2009. SDI Vector One\u00ae. Data extracted May, 2011. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/020592Orig1s040s041OtherR.pdf"},{"key":"3314_CR3","unstructured":"U.S. Food and Drug Administration. FDA Drug Safety Communication: 5-alpha reductase inhibitors (5-ARIs) may increase the risk of a more serious form of prostate cancer [Internet]. U.S. Food and Drug Administration, Silver Spring, c2013. Version 03\/2013. 10]. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm258314.htm"},{"key":"3314_CR4","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1177\/1557988314538445","volume":"9","author":"CA Ganzer","year":"2015","unstructured":"Ganzer CA, Jacobs AR, Iqbal F (2015) Persistent sexual, emotional, and cognitive impairment post-finasteride: a survey of men reporting symptoms. Am J Mens Health 9:222\u2013228","journal-title":"Am J Mens Health"},{"key":"3314_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.fertnstert.2019.11.030","volume":"113","author":"AM Traish","year":"2020","unstructured":"Traish AM (2020) Post-finasteride syndrome: a surmountable challenge for clinicians. Fertil Steril 113:21\u201350","journal-title":"Fertil Steril"},{"key":"3314_CR6","unstructured":"NIH (2015) Adverse events of 5-\u03b1-reductase inhibitors: US Department of Health and Human Services. Version 03\/03\/2015. https:\/\/rarediseases.info.nih.gov\/diseases\/12407\/adverse-events-of-5-alpha-reductase-inhibitors"},{"key":"3314_CR7","unstructured":"Administration USFD (2018) Questions and answers on FDA\u2019s adverse event reporting system (FAERS). Version 06\/04\/2018. https:\/\/www.fda.gov\/drugs\/surveillance\/questions-and-answers-fdas-adverse-event-reporting-system-faers"},{"key":"3314_CR8","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2147\/TCRM.S23889","volume":"7","author":"AK Ali","year":"2011","unstructured":"Ali AK (2011) Pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibitor. Ther Clin Risk Manag 7:337\u2013344","journal-title":"Ther Clin Risk Manag"},{"key":"3314_CR9","volume-title":"Principles of pharmacology: the pathophysiologic basis of drug therapy, 3rd revised international ed edition ed","author":"DETJA Golan","year":"2011","unstructured":"Golan DETJA, Armstrong EJ, Armstrong AW (2011) Principles of pharmacology: the pathophysiologic basis of drug therapy, 3rd revised international ed edition ed. Lippincott Williams and Wilkins, Philadelphia"},{"key":"3314_CR10","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/phar.1612","volume":"35","author":"AK Ali","year":"2015","unstructured":"Ali AK, Heran BS, Etminan M (2015) Persistent sexual dysfunction and suicidal ideation in young men treated with low-dose finasteride: a pharmacovigilance study. Pharmacotherapy 35:687\u2013695","journal-title":"Pharmacotherapy"},{"key":"3314_CR11","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1111\/j.1743-6109.2007.00563.x","volume":"4","author":"N Mondaini","year":"2007","unstructured":"Mondaini N, Gontero P, Giubilei G et al (2007) Finasteride 5 mg and sexual side effects: How many of these are related to a nocebo phenomenon? J Sex Med 4:1708\u20131712","journal-title":"J Sex Med"},{"key":"3314_CR12","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jaad.2006.05.007","volume":"55","author":"EA Olsen","year":"2006","unstructured":"Olsen EA, Hordinsky M, Whiting D et al (2006) The importance of dual 5\u03b1-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride vs. finasteride. J Am Acad Dermatol 55:1014\u20131023","journal-title":"J Am Acad Dermatol"},{"key":"3314_CR13","first-page":"484","volume":"75","author":"RS Rittmaster","year":"1992","unstructured":"Rittmaster RS, Lemay A, Zwicker H et al (1992) Effect of finasteride, a 5\u03b1-reductase inhibitor, on serum gonadotropins in normal men. J Clin Endocrinol Metab 75:484\u2013488","journal-title":"J Clin Endocrinol Metab"},{"key":"3314_CR14","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1210\/jc.2003-030330","volume":"89","author":"RV Clark","year":"2004","unstructured":"Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S (2004) Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5\u03b1-reductase inhibitor. J Clin Endocrinol Metab 89:2179\u20132184","journal-title":"J Clin Endocrinol Metab"},{"key":"3314_CR15","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S0090-4295(02)02401-9","volume":"61","author":"H Wessells","year":"2003","unstructured":"Wessells H, Roy J, Bannow J et al (2003) Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology 61:579\u2013584","journal-title":"Urology"},{"key":"3314_CR16","unstructured":"Physicians AAFP (2012) Finasteride sexual side effects prompt FDA warning, Label Changes. Version 04\/18\/2012. https:\/\/www.aafp.org\/news\/health-ofthe-public\/20120418finasteride.html"},{"key":"3314_CR17","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1111\/j.1743-6109.2010.02157.x","volume":"8","author":"AM Traish","year":"2011","unstructured":"Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML (2011) Adverse side effects of 5\u03b1-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med 8:872\u2013884","journal-title":"J Sex Med"},{"key":"3314_CR18","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1111\/ijcp.12908","volume":"70","author":"JP Mulhall","year":"2016","unstructured":"Mulhall JP, Luo X, Zou KH, Stecher V, Galaznik A (2016) Relationship between age and erectile dysfunction diagnosis or treatment using real-world observational data in the USA. Int J Clin Pract 70:1012\u20131018","journal-title":"Int J Clin Pract"},{"key":"3314_CR19","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/S0022-5347(05)67900-1","volume":"163","author":"CB Johannes","year":"2000","unstructured":"Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB (2000) Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol 163:460\u2013463","journal-title":"J Urol"},{"key":"3314_CR20","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S0090-4295(02)02158-1","volume":"61","author":"ED Moreira Jr","year":"2003","unstructured":"Moreira ED Jr, Lbo CF, Diament A, Nicolosi A, Glasser DB (2003) Incidence of erectile dysfunction in men 40 to 69 years old: results from a population-based cohort study in Brazil. Urology 61:431\u2013436","journal-title":"Urology"},{"key":"3314_CR21","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ajur.2017.06.004","volume":"4","author":"KB Lim","year":"2017","unstructured":"Lim KB (2017) Epidemiology of clinical benign prostatic hyperplasia. Asian J Urol 4:148\u2013151","journal-title":"Asian J Urol"},{"key":"3314_CR22","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.fertnstert.2016.12.018","volume":"107","author":"ML Eisenberg","year":"2017","unstructured":"Eisenberg ML, Meldrum D (2017) Effects of age on fertility and sexual function. Fertil Steril 107:301\u2013304","journal-title":"Fertil Steril"},{"issue":"Suppl 7","key":"3314_CR23","first-page":"S2","volume":"15","author":"Erectile dysfunction epidemiology","year":"2003","unstructured":"Erectile dysfunction epidemiology (2003) Int J Impot Res 15(Suppl 7):S2\u20134","journal-title":"Int J Impot Res"},{"key":"3314_CR24","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2147\/CLEP.S153458","volume":"10","author":"L Morin","year":"2018","unstructured":"Morin L, Johnell K, Laroche ML, Fastbom J, Wastesson JW (2018) The epidemiology of polypharmacy in older adults: register-based prospective cohort study. Clin Epidemiol 10:289\u2013298","journal-title":"Clin Epidemiol"},{"issue":"3","key":"3314_CR25","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1016\/j.urology.2010.07.142","volume":"76","author":"R Fourcade","year":"2010","unstructured":"Fourcade R, Lacoin F, Slama A, Gaudin A, Le Fur C, Michel E, Sitbon, Cott\u00e9 (2010) UP-1.09: impact of benign prostatic hyperplasia (BPH) on medically treated patients' quality of life. Urology 76(3):S55","journal-title":"Urology"},{"key":"3314_CR26","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1046\/j.1365-2133.1999.03030.x","volume":"141","author":"TF Cash","year":"1999","unstructured":"Cash TF (1999) The psychosocial consequences of androgenetic alopecia: a review of the research literature. Br J Dermatol 141:398\u2013405","journal-title":"Br J Dermatol"},{"issue":"Pt 3","key":"3314_CR27","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.2044-8295.1995.tb02756.x","volume":"86","author":"PA Wells","year":"1995","unstructured":"Wells PA, Willmoth T, Russell RJ (1995) Does fortune favour the bald? Psychological correlates of hair loss in males. Br J Psychol 86(Pt 3):337\u2013344","journal-title":"Br J Psychol"},{"key":"3314_CR28","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.urology.2018.06.022","volume":"120","author":"WR Baas","year":"2018","unstructured":"Baas WR, Butcher MJ, Lwin A et al (2018) A review of the FAERS data on 5-\u03b1 reductase inhibitors: implications for postfinasteride syndrome. Urology 120:143\u2013149","journal-title":"Urology"}],"updated-by":[{"DOI":"10.1007\/s00345-021-03824-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000}}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-020-03314-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-020-03314-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-020-03314-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T14:08:32Z","timestamp":1630505312000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-020-03314-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,28]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["3314"],"URL":"https:\/\/doi.org\/10.1007\/s00345-020-03314-9","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00345-021-03824-0","asserted-by":"object"}]},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,28]]},"assertion":[{"value":"6 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00345-021-03824-0","URL":"https:\/\/doi.org\/10.1007\/s00345-021-03824-0","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The author(s) declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The data used in this study are de-identified and publicly available FAERS data. It has been determined by the Institutional Review Board (IRB) at Weill Cornell Medical College that it meets eligibility for IRB review exemption authorized by 45 CFR part 46.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}